The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that strengthens Novo Nordisk's leadership in the obesity market, the European Commission has granted marketing authorization for the Wegovy pill (oral semaglutide 25 mg) as the first oral GLP-1 treatment in the EU. The approval also covers a 7.2 mg Wegovy injection in a single-dose pen, which demonstrated significant efficacy in clinical trials. These authorizations are based on data showing weight loss of 17% for the oral version and 21% for the higher-dose injection, providing patients with non-injectable alternatives for weight management.
This expansion comes amid intensifying competition with Eli Lilly’s Zepbound, as Novo Nordisk moves to secure its market share by diversifying administration methods. Per market data, NVO shares are trading at robust levels reflecting investor optimism regarding the pipeline, following significant revenue growth in the diabetes and obesity care segment last quarter. Analysts are closely monitoring the company's capacity to meet surging European demand, especially given the supply chain challenges that have previously impacted similar GLP-1 therapies globally.
Regarding equity performance, NVO stood at $49.07 and NONOF at $49.25 as of the close on July 14, 2026. In the German market, NOV.DE closed at €43.15 on July 13, 2026. With no immediate sector-specific catalysts in the upcoming economic calendar, investor focus will shift toward upcoming earnings reports to assess the financial impact of rolling out the oral weight-loss version across European markets.